Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Axicabtagene Ciloleucel in Large B-cell lymphoma: NCT06609304 Clinical Landscape Report 2026
15 October 2026
NCT06609304 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
![[177Lu]-MNPR-101 in Lung Cancer: NCT06617169 Clinical Landscape Report 2026](https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/Blog_cover_B_112_156d4a2e9d.jpg)
9 min read
[177Lu]-MNPR-101 in Lung Cancer: NCT06617169 Clinical Landscape Report 2026
15 October 2026
NCT06617169 clinical landscape for Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zedoresertib in Triple Negative Breast Cancer: NCT06612203 Clinical Landscape Report 2026
15 October 2026
NCT06612203 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fluciclovine 18F in Glioblastoma Multiforme: NCT06613841 Clinical Landscape Report 2026
15 October 2026
NCT06613841 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pegfilgrastim (Amgen) in Neutropenia: NCT06616987 Clinical Landscape Report 2026
15 October 2026
NCT06616987 clinical landscape for Neutropenia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
THEO-260 in Ovarian Cancer: NCT06618235 Clinical Landscape Report 2026
15 October 2026
NCT06618235 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Paclitaxel in Ovarian Cancer: NCT06620029 Clinical Landscape Report 2026
15 October 2026
NCT06620029 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in Triple Negative Breast Cancer: NCT06618014 Clinical Landscape Report 2026
15 October 2026
NCT06618014 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tocilizumab in Diffuse Large B-Cell Lymphoma: NCT06624085 Clinical Landscape Report 2026
15 October 2026
NCT06624085 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ambroxol Hydrochloride in Neurodegenerative Diseases: ACTRN12624001204538 Clinical Landscape Report 2026
15 October 2026
ACTRN12624001204538 clinical landscape for Neurodegenerative Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Fludarabine Phosphate in Metastatic Renal Cell Carcinoma: NCT06626256 Clinical Landscape Report 2026
15 October 2026
NCT06626256 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma: NCT06625047 Clinical Landscape Report 2026
15 October 2026
NCT06625047 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.